# Sunitinib

## Sutent 12.5mg

#### 個案臨採

| 藥品代碼       | OSUT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|:---------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症         | Treatment of GI stromal tumor after disease progression on or intolerance to imatinib mesylate. Treatment of advanced or metastatic renal cell carcinoma (clear cell carcinoma in pathology).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 用法用量       | [Gastrointestinal Stromal Tumor (GIST) and Advanced Renal Cell Carcinoma (RCC)] 50 mg orally with or without food once daily， on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2). [Pancreatic neuroendocrine tumors (pNET)] 37.5 mg orally with or without food once daily continuously without a scheduled off-treatment period. [Adjuvant Treatment of RCC] 50 mg orally with or without food once daily， on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2)， for nine 6-week cycles.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 肝功能異常     | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 腎功能異常     | 需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 禁忌           | Pregnancy. Women of childbearing potential should avoid becoming pregnant while receiving treatment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 副作用         | Fatigue， asthenia， diarrhea， nausea， mucositis/stomatitis， vomiting， dyspensia， abdominal pain， constipation， hypertension， rash， hand-foot syndrome， skin discoloration， altered taste， anorexia & bleeding. Potentially serious adverse reactions of LV dysfunction， QT interval prolongation， hemorrhage， hypertension & adrenal dysfunction. Dermatologic: Discoloration of skin， Yellow (GIST， 30%; MRCC， 19% )， Dry skin (MRCC， 18% )， Rash (GIST， 14%; MRCC， 27% ) Endocrine metabolic: Hypothyroidism (GIST， 4% to 36%; MRCC， 3% ) Gastrointestinal: Abdominal pain (MRCC， 22% )， Constipation (GIST， 20%; MRCC， 16% )， Diarrhea (GIST， 40%; MRCC， 58% )， Increased serum lipase level (GIST， 25%; MRCC， 52% )， Indigestion (MRCC， 28% )， Inflammatory disease of mucous membrane (GIST， 29%; MRCC， 43% )， Loss of appetite (GIST， 33%; MRCC， 38% )， Nausea (MRCC， 49% )， Pain of oral cavity structure (GIST， 6%; MRCC， 10% )， Taste sense altered (GIST， 21%; MRCC， 44% )， Vomiting (MRCC， 28% ) Hematologic: Anemia (GIST， 26%; MRCC， 71% )， Bleeding (GIST， 18%; MRCC， 30% )， Leukopenia (MRCC， 78% )， Lymphocytopenia (GIST， 38%; MRCC， 59% )， Neutropenic disorder (GIST， 53%; MRCC， 72% ) Hepatic: Liver function tests abnormal (GIST， 10% to 39%; MRCC， 13% to 56% ) Neurologic: Asthenia (GIST， 22%; MRCC， 21% ) Renal: Increased uric acid level (MRCC， 41% ) |
| 孕期用藥建議   | nan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 哺乳期用藥建議 | No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

